AstraZeneca Oncology Deal History & Licensing Activity
AstraZeneca Oncology is a large pharma headquartered in UK. Over the past three years, AstraZeneca Oncology has been involved in 4 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 21 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
21
Top Modality
Small Molecules
Focus Area
Solid Tumors
AstraZeneca Oncology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AstraZeneca Oncology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| obesity and weight-related drug candidates | AstraZeneca | Other | Unknown | collaboration | Jun 27, 2026 |
| JAB-23E73 | AstraZeneca | Small Molecules | Unknown | license | Apr 29, 2026 |
| EGFR degrader | AstraZeneca | Small Molecules | Unknown | license |
AstraZeneca Oncology Pipeline Focus
Therapeutic areas and modalities where AstraZeneca Oncology is most active based on deal history and clinical trial data.
AstraZeneca Oncology Strategic Signals
Key indicators of AstraZeneca Oncology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
AstraZeneca Oncology Clinical Pipeline
AstraZeneca Oncology has 21 active clinical trials across 4 development phases.
5
Unknown
1
Phase 1
9
Phase 2
6
Phase 3
See How Your Asset Matches AstraZeneca Oncology's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About AstraZeneca Oncology Licensing & Deal Activity
AstraZeneca Oncology is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, AstraZeneca Oncology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AstraZeneca Oncology include Solid Tumors (15 deals and trials), Metabolic (3 deals and trials), Oncology (2 deals and trials), and Other (2 deals and trials). In terms of modality, AstraZeneca Oncology has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AstraZeneca Oncology and 850+ other biopharma companies. Use our Solidus to benchmark your asset against AstraZeneca Oncology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.